Skip to main content
. Author manuscript; available in PMC: 2011 Oct 1.
Published in final edited form as: Pharmacogenomics J. 2010 Mar 2;11(2):146–154. doi: 10.1038/tpj.2010.12

Table 1.

Demographics by remission status at 3-months

Remitted N = 71 Nonremitted N = 158 Test value p value
BDNF (% Met/*) 31.0 % (22/71) 43.0% (68/158) χ2 = 2.98 0.0842
Age 68.8 (7.2) 69.7 (7.5) t = 0.82 0.4133
Age of onset 44.4 (18.7) 44.5 (21.2) t = 0.04 0.9664
Sex (% Female) 66.2% (47/71) 62.0% (98/158) χ2 = 0.37 0.5446
Education 13.9 (2.9) 13.7 (2.7) t = 0.70 0.4855
MMSE 28.3 (2.1) 28.1 (2.2) t = 0.39 0.6999
MADRS, baseline 26.7 (8.2) 27.0 (7.8) t = 0.24 0.8078
CIRS 4.1 (3.1) 4.5 (3.1) t = 0.90 0.3707
IADL score 2.9 (4.5) 3.7 (4.7) t = 1.17 0.2443
Subjective SS (Unadjusted) 24.3 (3.6) 22.6 (4.1) t = 2.92 0.0039
Subjective SS (Log) 3.2 (0.2) 3.1 (0.2) t = 3.12 0.0021
WML volume 6.1 (12.3) 7.6 (10.9) t = 0.76 0.4460

All comparisons of continuous variables used pooled, two-tailed t-tests with 227 df, except for analyses of subjective social support which used a Satterthwaite t-test with 162 df due to unequal variances. Age and education variables presented in years, white matter hyperintense lesion (WML) volume presented in milliliters.